Tag:
PML
Latest Headlines
Latest Headlines
Novartis reports patient taking Gilenya developed rare brain disease
Expectations for the blockbuster status of Gilenya dimmed when Novartis disclosed that a patient taking the drug has developed a rare brain disease.
Quest's companion diagnostic confronts Tysabri brain infection risk
It's a vexing problem that certain drugs with enormous benefit can also carry significant health risk. Case in point: Some patients who take the multiple sclerosis drug Tysabri experience improved
FDA: Tysabri risks greatest during year 3
The FDA has updated its warning on Biogen Idec's multiple sclerosis drug Tysabri. According to the agency, the risk of a potentially fatal brain infection appears to be greatest during the third year
Tysabri safety falls under EMEA scrutiny
European regulators are taking a hard look at the multiple sclerosis wonder drug Tysabri. Spurred by 23 cases of the brain disease PML that have cropped up since Tysabri went back on the market in
Biogen, Elan push back on Tysabri study
Biogen Idec and Elan are soft-pedaling research released yesterday that showed the virus responsible for a potentially fatal brain disorder is activated--and the patient's immune system weakened--by
Researchers identify Tysabri-PML link
The multiple sclerosis drug Tysabri awakens a virus that causes a rare brain disease, not only suppressing the body's ability to fight it but making the virus stronger, U.S. researchers found. Report
Latest PML case sets Biogen investors off
Analysts are increasingly skeptical of Biogen Idec, as each weekly Tysabri update turns up another patient with the potentially deadly brain infection PML. As you know, the company announced Friday
Biogen flags sixth case of PML
Biogen Idec reported a sixth case of the potentially fatal brain disease progressive multifocal leukoencephalopathy, or PML, in a multiple sclerosis patient taking its drug Tysabri. According to Dow
Genentech pulls Raptiva on PML fears
It's the start of a long goodbye for Genentech's psoriasis remedy Raptiva. The company said it's phasing out the drug because of recent reports of the potentially fatal brain infection progressive
EMEA: Raptiva PML risks outweigh benefits
Sobering news on Genentech's psoriasis med Raptiva: Another case of the rare brain disease PML (progressive multifocal leukocephalopathy) has cropped up in a patient using the drug, marketed in
